|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-7-21
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
We have recently reported successful treatment of patients with chronic pain syndromes using human pooled intravenous immunoglobulin (IVIG) in a prospective, open-label cohort study. A randomised, placebo controlled, double blinded study is needed to confirm these results. We chose to study patients with carbamazepine resistant primary Trigeminal Neuralgia (rpTN), as these had responded particularly well to IVIG.A protocol involving the use of IVIG in rpTN is complex for three reasons: 1. The effect of IVIG does not follow simple dose-response rules; 2. The response pattern of patients to IVIG was variable and ranged between no effect at all and pain free remission between two weeks and >1 year; 3. TN is characterized by extremely severe pain, for which operative intervention is (if temporarily) helpful in most patients.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-10514226,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-11071491,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-11402108,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-11446385,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-11460800,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-11580867,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-11690728,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-11803299,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-15102158,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-2250496,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-7580659,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-8193882,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-8247075,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-8598865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-9415509,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12590652-9474717
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1471-2377
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
30
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Intravenous immunoglobulin in the treatment of primary trigeminal neuralgia refractory to carbamazepine: a study protocol [ISRCTN33042138].
|
|
pubmed:affiliation |
Nuffield Department of Anaesthetics, University of Oxford, Oxford OX3 9DU, England, UK. andreasgoebel@rocketmail.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
